Literature DB >> 2843986

A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons.

A I Geller1, X O Breakefield.   

Abstract

A defective herpes simplex virus 1 (HSV-1) vector, pHSVlac, has been developed that contains a transcription unit that places the Escherichia coli lacZ gene under the control of the HSV-1 immediate early 4/5 promoter. The vector pHSVlac was propagated with the HSV-1 temperature-sensitive mutant ts K as helper virus. Infection of neurons from rat superior cervical ganglia and dorsal root ganglia in primary culture resulted in stable expression of high levels of beta-galactosidase without cell death. These HSV-1 vectors should be useful for introducing genes into postmitotic cells, such as neurons, in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843986      PMCID: PMC2581874          DOI: 10.1126/science.2843986

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  29 in total

1.  Acute infection of differentiated neuroblastoma cells by latency-positive and latency-negative herpes simplex virus ts mutants.

Authors:  J C Gerdes; H S Marsden; M L Cook; J G Stevens
Journal:  Virology       Date:  1979-04-30       Impact factor: 3.616

2.  Transformation of mammalian cells with genes from procaryotes and eucaryotes.

Authors:  M Wigler; R Sweet; G K Sim; B Wold; A Pellicer; E Lacy; T Maniatis; S Silverstein; R Axel
Journal:  Cell       Date:  1979-04       Impact factor: 41.582

3.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

4.  Cells that constitutively express the herpes simplex virus immediate-early protein ICP4 allow efficient activation of viral delayed-early genes in trans.

Authors:  R H Persson; S Bacchetti; J R Smiley
Journal:  J Virol       Date:  1985-05       Impact factor: 5.103

5.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

6.  Nucleotide sequences of the joint between the L and S segments of herpes simplex virus types 1 and 2.

Authors:  A J Davison; N M Wilkie
Journal:  J Gen Virol       Date:  1981-08       Impact factor: 3.891

7.  The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector.

Authors:  R R Spaete; N Frenkel
Journal:  Cell       Date:  1982-08       Impact factor: 41.582

8.  Long-term culture of dissociated sympathetic neurons.

Authors:  E Hawrot; P H Patterson
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

9.  Latency competence of thirteen HSV-1 temperature-sensitive mutants.

Authors:  K Watson; J G Stevens; M L Cook; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1980-07       Impact factor: 3.891

10.  Monoclonal antibody to a plasma membrane antigen of neurons.

Authors:  G S Eisenbarth; F S Walsh; M Nirenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

View more
  72 in total

1.  Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry.

Authors:  D B Anderson; S Laquerre; K Ghosh; H P Ghosh; W F Goins; J B Cohen; J C Glorioso
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Characterization of promoter function and cell-type-specific expression from viral vectors in the nervous system.

Authors:  R L Smith; D L Traul; J Schaack; G H Clayton; K J Staley; C L Wilcox
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  MRI of transgene expression: correlation to therapeutic gene expression.

Authors:  Tomotsugu Ichikawa; Dagmar Högemann; Yoshinaga Saeki; Edyta Tyminski; Kinya Terada; Ralph Weissleder; E Antonio Chiocca; James P Basilion
Journal:  Neoplasia       Date:  2002 Nov-Dec       Impact factor: 5.715

Review 4.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 5.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

6.  Targeted gene transfer to nigrostriatal neurons in the rat brain by helper virus-free HSV-1 vector particles that contain either a chimeric HSV-1 glycoprotein C-GDNF or a gC-BDNF protein.

Authors:  Xiaodan Wang; Lingxin Kong; Guo-rong Zhang; Mei Sun; Alfred I Geller
Journal:  Brain Res Mol Brain Res       Date:  2005-09-13

Review 7.  Molecular analysis of the function of the neuronal growth-associated protein GAP-43 by genetic intervention.

Authors:  R L Neve; K J Ivins; L I Benowitz; M J During; A I Geller
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

8.  Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival.

Authors:  Caryl E Sortwell; William J Bowers; Scott E Counts; Mark R Pitzer; Matthew F Fleming; Susan O McGuire; Kathleen A Maguire-Zeiss; Howard J Federoff; Timothy J Collier
Journal:  Brain Res       Date:  2006-12-28       Impact factor: 3.252

Review 9.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

10.  Assessment of a cellular vaccination approach consisting of crawling dendritic cells (CDCs) transduced with HSV-1-Deltapac vectors.

Authors:  Rafael Nuñez; Cornel Fraefel; Mark Suter; Anne Nuñez-Liman; Hsiou-Chi Liou; Mathias Ackerman
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.